Nancie M Archin1, David M Margolis. 1. Institute for Global Health and Infectious Diseases, and Center for AIDS Research, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, USA.
Abstract
PURPOSE OF REVIEW: This review highlights recent studies undertaken to further advance the search for successful approaches to eradicate HIV infection. RECENT FINDINGS: Small pharmacological compounds such as histone deacetylase inhibitors, inhibitors of bromodomain and extraterminal proteins such as JQ1, and protein kinase C activators such as bryostatin and prostratin are proposed as putative candidates for inducing the expression of latent HIV in a so-called 'shock and kill' or 'kick and kill' strategy for HIV eradication. However, in order to achieve viral clearance, it is thought likely these compounds will have to be administered in concert with strategies that augment clearance of virus-infected cells in patients that have long been aviremic on successful antiretroviral therapy (ART). Several candidate therapies for this purpose are at hand, such as therapeutic HIV vaccines - recently shown to promote robust cytotoxic T cell responses and blunt viral rebound after ART interruption in clinical studies. HIV-infected patients treated during early infection may be ideal candidates for early studies to test these strategies, as early ART has been shown to limit the establishment of an HIV reservoir. SUMMARY: HIV latency is multifactorial and thus the eradication of HIV infection may require multiple approaches. Translational efforts employing pharmacological methods to target HIV latency should evaluate in parallel the additional potential benefits of invigorating the immune response of HIV-infected individuals, and limiting the size of the reservoir via early ART.
PURPOSE OF REVIEW: This review highlights recent studies undertaken to further advance the search for successful approaches to eradicate HIV infection. RECENT FINDINGS: Small pharmacological compounds such as histone deacetylase inhibitors, inhibitors of bromodomain and extraterminal proteins such as JQ1, and protein kinase C activators such as bryostatin and prostratin are proposed as putative candidates for inducing the expression of latent HIV in a so-called 'shock and kill' or 'kick and kill' strategy for HIV eradication. However, in order to achieve viral clearance, it is thought likely these compounds will have to be administered in concert with strategies that augment clearance of virus-infected cells in patients that have long been aviremic on successful antiretroviral therapy (ART). Several candidate therapies for this purpose are at hand, such as therapeutic HIV vaccines - recently shown to promote robust cytotoxic T cell responses and blunt viral rebound after ART interruption in clinical studies. HIV-infectedpatients treated during early infection may be ideal candidates for early studies to test these strategies, as early ART has been shown to limit the establishment of an HIV reservoir. SUMMARY: HIV latency is multifactorial and thus the eradication of HIV infection may require multiple approaches. Translational efforts employing pharmacological methods to target HIV latency should evaluate in parallel the additional potential benefits of invigorating the immune response of HIV-infected individuals, and limiting the size of the reservoir via early ART.
Authors: Samuel A Williams; Lin-Feng Chen; Hakju Kwon; David Fenard; Dwayne Bisgrove; Eric Verdin; Warner C Greene Journal: J Biol Chem Date: 2004-07-28 Impact factor: 5.157
Authors: K R Gustafson; J H Cardellina; J B McMahon; R J Gulakowski; J Ishitoya; Z Szallasi; N E Lewin; P M Blumberg; O S Weislow; J A Beutler Journal: J Med Chem Date: 1992-05-29 Impact factor: 7.446
Authors: D E Schaufelberger; M P Koleck; J A Beutler; A M Vatakis; A B Alvarado; P Andrews; L V Marzo; G M Muschik; J Roach; J T Ross Journal: J Nat Prod Date: 1991 Sep-Oct Impact factor: 4.050
Authors: S Mémet; D Laouini; J C Epinat; S T Whiteside; B Goudeau; D Philpott; S Kayal; P J Sansonetti; P Berche; J Kanellopoulos; A Israël Journal: J Immunol Date: 1999-12-01 Impact factor: 5.422
Authors: D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano Journal: Science Date: 1997-11-14 Impact factor: 47.728
Authors: Deborah Persaud; Hannah Gay; Carrie Ziemniak; Ya Hui Chen; Michael Piatak; Tae-Wook Chun; Matthew Strain; Douglas Richman; Katherine Luzuriaga Journal: N Engl J Med Date: 2013-10-23 Impact factor: 91.245
Authors: Li Liu; Bhavik Patel; Mustafa H Ghanem; Virgilio Bundoc; Zhili Zheng; Richard A Morgan; Steven A Rosenberg; Barna Dey; Edward A Berger Journal: J Virol Date: 2015-04-15 Impact factor: 5.103
Authors: Debbie S Ruelas; Jonathan K Chan; Eugene Oh; Amy J Heidersbach; Andrew M Hebbeler; Leonard Chavez; Eric Verdin; Michael Rape; Warner C Greene Journal: J Biol Chem Date: 2015-04-14 Impact factor: 5.157
Authors: Jennifer T Miller; Haiyan Zhao; Takashi Masaoka; Brittany Varnado; Elena M Cornejo Castro; Vickie A Marshall; Kaivon Kouhestani; Anna Y Lynn; Keith E Aron; Anqi Xia; John A Beutler; Danielle R Hirsch; Liang Tang; Denise Whitby; Ryan P Murelli; Stuart F J Le Grice Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191
Authors: Brian Reardon; Nadejda Beliakova-Bethell; Celsa A Spina; Akul Singhania; David M Margolis; Douglas R Richman; Christopher H Woelk Journal: AIDS Date: 2015-11 Impact factor: 4.177